The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction and stroke after an episode of worsening heart failure in patients with heart failure, sinus rhythm and coronary artery disease. These conclusions came from late-breaking results from the COMMANDER HF trial presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2018, Aug. 25-28 in Munich, Germany, and with simultaneous publication in the New England Journal of Medicine.1